<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Intravitreales Aflibercept 8 mg - PHOTON</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
  <link rel="stylesheet" href="assets/css/styles.css">
  <link rel="stylesheet" href="assets/fonts/fontawesome-all.min.css">
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.0/jquery.min.js"></script>
  <script src="assets/js/javascript.js"></script>
</head>

<body>
  <div class="row">
    <h3 style="font-size: 28px; width: 100%; color: white; font-weight: bold; background: #00617f; padding-top: 10px; padding-bottom: 10px;padding-left: 25px;">Intravitreal Aflibercept 8 mg - PHOTON</h3>
  </div>

    
  <div>
    <button type="button" class="btn btn-back" id="back_button" onclick="location.href='index.html';">IVT-AFL 8 mg Overview</button><br>
    <h4>
      PHOTON
    </h4>
    <div class="card">
      <ul class="nav nav-tabs" role="tablist">
        <li class="nav-item" role="presentation"><a class="nav-link active" id="summary_tab" data-bs-toggle="tab" data-bs-target="#summary" href="#summary" role="tab">Zusammenfassung</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "design_tab" data-bs-toggle="tab" data-bs-target="#design" href="#design" role="tab">Design</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "results_tab" role="tab" data-bs-toggle="tab" href="#results">Results</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "safety_tab" role="tab" data-bs-toggle="tab" href="#safety">Safety</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id = "reference_tab" role="tab" data-bs-toggle="tab" href="#reference">References</a>
        </li>
      </ul>
    </div>
  
    <div class="tab-content">
      <div id="summary" class="tab-pane show active" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Zusammenfassung<sup>1,2</sup>
          </h1>
          <ul class="bullet">
            <li>
              PHOTON ist eine randomisierte, doppelblinde Phase-II/III-Studie zur Bewertung des Wirksamkeits- und Sicherheitsprofils einer IVT-AFL 8 mg-Formulierung im Vergleich zu IVT-AFL 2 mg zur Behandlung von DME.
            </li>
            <li>
              PHOTON ist als 96-wöchige Studie geplant und <a href="https://www.clinicaltrials.gov/study/NCT04429503" target="_blank">läuft noch</a>.
            </li>
            <br>
            <p style="margin-left: -25px; margin-bottom: 0px;">
              <b>Woche 48 Wirksamkeit<sup>1</sup></b>
            </p>
            <li>
              Der primäre Endpunkt wurde erreicht - beide 8-mg-Gruppen zeigten eine nicht unterlegene BCVA-Veränderung im Vergleich zu 2 mg:
              <ul>
                <li>
                  Die mittlere Veränderung der BCVA von Baseline bis Woche 48 betrug 8.1, 7.2 bzw. 8.7 ETDRS-Buchstaben in den Gruppen 8q12, 8q16 und 2q8.
                </li>
              </ul>
            </li>
            <br>
            <p style="margin-left: -25px; margin-bottom: 0px;">
              <b>Woche 96 Wirksamkeit<sup>2</sup></b>
            </p>
            <li>
              Beide 8-mg-Gruppen zeigten im Vergleich zu 2 mg eine nicht unterlegene BCVA-Veränderung:
            </li>
              <ul>
                <li>
                  Die mittlere Veränderung der BCVA von Baseline bis Woche 96 betrug 8.2, 6.6 bzw. 7.7 ETDRS-Buchstaben in den Gruppen 8q12, 8q16 und 2q8.
                </li>
              </ul> 
              <br> 
            <p style="margin-left: -25px; margin-bottom: 0px;">
              <b>Sicherheit<sup>1,2</sup></b>
            </p>
            <li>
              Es wurde festgestellt, dass das Sicherheitsprofil von IVT-AFL 8 mg in den Wochen 48 und 96 dem von IVT-AFL 2 mg ähnlich ist.
            </li>
          </ul>          
        </div><br><br>
      </div>
  
      <div id="design" class="tab-pane"  role="tabpanel">
        <div class="container-fluid">
          <h1>
            Design<sup>1,2</sup>
          </h1>
          <ul class="bullet">        
            <li>
              Adults with DME with central involvement with CRT &ge;300 µm (or &ge;320 µm on Spectralis) and BCVA of 78-24 letters (Snellen equivalent 20/32-20/320) with decreased vision due to DME were enrolled.
            </li>
            <li>
              Patients were randomized 2:1:1 to receive IVT-AFL 8q12 or 8q16 after 3 initial monthly injections, or IVT AFL 2q8 after 5 initial monthly injections.
            </li>
            <li>
              Dosing regimen modifications were permitted starting at Week 16 for the IVT-AFL 8 mg groups, based on prespecified criteria.
            </li>
          </ul>
          <div class="container-collapse">
            <a class="btn btn-collapse" data-bs-toggle="collapse" aria-expanded="false" aria-controls="collapse-1" href="#collapse-1" role="button">Click to Expand/Collapse <br> Dosing Regimens
            </a>
          </div>
  
            <div id="collapse-1" class="collapse">
              <h2>
                Treatment Groups and Dosing Regimens Through Week 96
              </h2>
              <div class="figure zoom">
                <img src="assets/img/dosing-PHOTON.PNG" 
                class="img-fluid">
            </div>
          </div>
        </div><br><br>
      </div> 
            
      <div id="results" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Results
          </h1>
          <div class="accordion">
            <div class="accordion-item">
              <h2 class="accordion-header" id="heading 1">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-2">
                 Patients
                </button>
              </h2>
              <div id="collapse-2" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <div class="container-collapse">
                    <a class="btn btn-collapse-white" data-bs-toggle="collapse" aria-expanded="false" href="#collapse-3" role="button">Click to Expand/Collapse <br> Baseline Demographics
                    </a>
                  </div>
          
                  <div id="collapse-3" class="collapse">
                    <h2>
                      Baseline Demographics (FAS)
                    </h2>
                    <div class="figure-white">
                      <img src="assets/img/baseline-PHOTON.PNG"
                      class="img-fluid">
                    </div>
                  </div>

                  <p style="margin-left: 10px; margin-top: -10px; font-size: 20px;">
                    328 patients were randomized to 8q12, 163 to 8q16, and 167 to 2q8.<sup>1</sup>
                  </p>
                  <p style="margin-left: 10px; font-size: 20px; font-weight: bold;">
                    Week 48<sup>1</sup>
                  </p>
                  <ul class="bullet-collapse">
                    <li>
                      Completion rates were 91.2% for 8q12, 95.1% for 8q16, and 94.0% for 2q8.
                    </li>
                    <li>
                      Mean number of injections were 5.7 for 8q12, 4.9 for 8q16, and 7.7 for 2q8. 
                    </li>
                    <li>
                      93% of 8 mg patients maintained extended dosing of &ge;12 weeks.
                    </li>
                  </ul>

                  <p style="margin-left: 10px; font-size: 20px; font-weight: bold;">
                    Week 96<sup>2</sup>
                  </p>
                  <ul class="bullet-collapse">                    
                    <li>
                      Completion rates were 77.8% for 8q12, 84.8% for 8q16, and 83.2% for 2q8. 
                    </li>
                    <li>
                      Mean number of injections were 9.5 for 8q12, 7.8 for 8q16, and 13.8 for 2q8. 
                    </li>
                    <li>
                      89% of 8 mg patients maintained extended dosing of &ge;12 weeks.
                    </li>
                    <li>
                      44% of 8 mg patients had assigned dosing intervals of &ge;20 weeks at Week 96.
                    </li>
                  </ul>
                </div>
              </div>
            </div>
              
            <div class="accordion-item">
              <h2 class="accordion-header" id="patients">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-4">
                  Visual Outcomes
                </button>
              </h2>
              <div id="collapse-4" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <ul class="bullet-collapse">
                    <li>
                       Both 8 mg groups had non-inferior mean BCVA change compared to 2q8 at Week 48 (primary endpoint) and Week 96.<sup>1,2</sup>
                    </li>
                  </ul>
                  <h2>
                    Mean Change in BCVA (FAS)<sup style="top: -0em">2</sup>
                  </h2>
                  <div class="figure-white">
                    <img src="assets/img/primary_outcome-PHOTON.PNG" 
                        class="img-fluid">
                  </div>
                </div>
              </div>
            </div>
  
            <div class="accordion-item">
              <h2 class="accordion-header" id="results">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-5">
                  Key Secondary Endpoints
                </button>
              </h2>
              <div id="collapse-5" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <h2>
                     Key Secondary Endpoint Results (FAS)<sup style="top: -0em">1,2</sup>
                  </h2>
                  <div class="figure-white">
                    <img src="assets/img/secondary_outcomes-PHOTON.PNG" 
                      class="img-fluid">
                  </div>
                </div>
              </div>
            </div>
          </div><br>
        </div>
      </div>
      
      <div id="safety" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Safety
          </h1>
          <ul class="bullet">
            <li>
              The safety profile of IVT-AFL 8 mg was found to be similar to that of IVT-AFL 2 mg at Weeks 48 and 96.<sup>1,2</sup>
            </li>
            <li>
              Ocular AEs occurring in &ge;5% of patients through 96 weeks in any treatment group were cataract, vitreous floaters, and conjunctival hemorrhage.<sup>2</sup>
            </li>
          </ul>
          <h2>
            AEs through Week 96 (SAF)<sup style="top: -0em">2</sup>
          </h2>
          <div class="figure">
            <img src="assets/img/safety-PHOTON.PNG" 
              class="img-fluid">
          </div>
        </div>
      </div>
  
      <div id="reference" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            References
          </h1>
          <ol style="margin-left: 30px; margin-right: 30px; margin-top: -20px; padding-right: 30px; padding-left: 30px; padding-bottom: 10px; padding-top: 10px; font-size: 20px;background-color: #f7f7f7;">
            <li>
              Brown DM. Intravitreal Aflibercept Injection 8 mg for DME:
              48-Week Results From the Phase 2/3 PHOTON Trial. Presented at: 55th Annual Scientific Meeting of The Retina Society; November 2-5, 2022; Pasadena, CA. 
              <br><a href="https://investor.regeneron.com/static-files/c0c47d3b-926b-44f9-8d9a-5a3a3fd3bdd0" target="_blank">Link</a>
            </li>
            <li>
              Do DV. Aflibercept 8 mg for Diabetic Macular Edema:
              2-Year Results of the Phase 2/3 PHOTON Trial. Presented at: American Society of Retina Specialists; July 28-Aug 1, 2023; Palo Alto, CA. 
              <br><a href="https://investor.regeneron.com/static-files/c5aea914-bada-4d6f-8742-817e319b972f" target="_blank">Link</a>
            </li>
          </ol>
        </div>
      </div><br><br>
    </div>
  
    <footer class="fixed-bottom">
      <div class="container-fluid">
        <button type="button" class="btn btn-abbrev" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" onclick="changeIcon(this)" title="Abbreviations" data-bs-content="
          <strong>2q8</strong> 2 mg every 8 weeks<br>
          <strong>8q12</strong> 8 mg every 12 weeks<br>
          <strong>8q16</strong> 8 mg every 16 weeks<br>
          <strong>AE</strong> adverse event<br>
          <strong>APTC</strong> Anti-Platelet Trialists' Collaboration<br>
          <strong>BCVA</strong> best-corrected visual acuity<br>
          <strong>CI</strong> confidence interval<br>
          <strong>CRT</strong> central retinal thickness<br>
          <strong>DME</strong> diabetic macular edema<br>
          <strong>DRM</strong> dose regimen modification<br>
          <strong>DRSS</strong>  diabetic retinopathy severity scale<br>
          <strong>ETDRS</strong> Early Treatment Diabetic Retinopathy Study<br>
          <strong>FAS</strong> full analysis set<br>
          <strong>IOI</strong> intraocular inflammation<br>
          <strong>IOP</strong> intraocular pressure<br>
          <strong>IRF</strong> intraretinal fluid<br>
          <strong>IVT-AFL</strong> intravitreal aflibercept<br>
          <strong>LS</strong> least squares<br>
          <strong>n</strong> number<br>
          <strong>pts</strong> patients<br>
          <strong>q24</strong> every 24 weeks<br>
          <strong>SAE</strong> serious adverse events<br>
          <strong>SAF</strong> safety analysis set<br>
          <strong>SRF</strong> subretinal fluid<br>">
        <i id ="fa" class="fas fa-list"></i>
        </button>
  
    <button type="button" class="btn btn-ref" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" title="References" onclick="changeIcon(this)" data-bs-content="
      <ol>
        <li>
          Brown DM. Intravitreal Aflibercept Injection 8 mg for DME:
          48-Week Results From the Phase 2/3 PHOTON Trial. Presented at: 55th Annual Scientific Meeting of The Retina Society; November 2-5 2022; Pasadena, CA. 
          <br><a href='https://investor.regeneron.com/static-files/c0c47d3b-926b-44f9-8d9a-5a3a3fd3bdd0' target='_blank'>Link</a>
        </li>
        <li>
          Do DV. Aflibercept 8 mg for Diabetic Macular Edema:
          2-Year Results of the Phase 2/3 PHOTON Trial. Presented at: American Society of Retina Specialists; July 28-Aug 1, 2023; Palo Alto, CA. 
          <br><a href='https://investor.regeneron.com/static-files/c5aea914-bada-4d6f-8742-817e319b972f' target='_blank'>Link</a>
        </li>
     </ol>">
     <i id="fa" class="fas fa-scroll"></i>
    </button>
      </div>
      <a href="#" id="scroll" style="display: none;"><span></span></a>
    </footer>   
  </div>
</div>

<script>  
  var popoverTriggerList = [].slice.call(document.querySelectorAll('[data-bs-toggle="popover"]'))
  var popoverList = popoverTriggerList.map(function (popoverTriggerEl) 
  {
    return new bootstrap.Popover(popoverTriggerEl)
  });
</script>
</body>

</html>